Pox virus MART-1 vaccine (Recombinant, Therion/Sanofi)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePox virus MART-1 vaccine (Recombinant, Therion/Sanofi)

Drug Alias NamerF-MART-1

ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Biological material > Viral vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionMelanoma antigen recognized by T-cells 1 modulators

TargetsMelanoma antigen recognized by T-cells 1

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTherion Biologics Sanofi

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTherion Biologics Sanofi

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A